lung cancer
Conditions
Interventions
Fast drug resistance group and slow drug resistance group:Treatment according to the guidelines, without any other intervention
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) First diagnosed patients who had not received any antineoplastic treatment before; (2) According to the new histological classification of lung tumors published by the World Health Organization (WHO) in 2015, pathological diagnosis of NSCLC was confirmed; (3) According to the eighth edition of the International Association for the Study of Lung Cancer (IASLC) staging criteria for cancer-node-metastasis (TNM) of lung cancer in 2015, the clinical staging is stages IIIB, IIIC and IV, mainly for stage IV inoperable patients; (4) According to NCCN lung cancer guidelines, EGFR mutations were detected to be positive; (5) willing to receive EGFR-TKI targeted therapy; (6) aged > 18 years old.
Exclusion criteria
Exclusion criteria: (1) Histological diagnosis was non-NSCLC; (2) TNM stage was I-IIIA, which could be operated on; (3) Driving gene test was negative; (4) Severe liver and kidney dysfunction; (5) Expected survival time < 3 months; (6) Received other antineoplastic treatments in the past; (7) unwilling to join the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;Image indexes group; | — |
Countries
China
Contacts
Public ContactLi Weimin
West China Hospital, Sichuan University
Outcome results
None listed